Research Grants is sponsored by Merck Group. Merck offers research grants to encourage innovation in key areas.

While the specific categories for 2026 mentioned in the search results (in-vitro models for neuroinflammatory diseases, AI in cell culture media, economical remediation of contaminated materials, cell-free screening assays, and advancing molecule synthesis) do not explicitly list 'neoantigen cancer immunotherapy,' innovative approaches within drug discovery and biotechnology that could impact neoantigen research might be considered.

digi·access - Improve accessibility Optimize the website for better readability and user experience.

The page is reloaded when used Adjustments for accessibility **Visually impaired people**Support for people with poor eyesight **Reading texts aloud**Assistance for users who have problems reading online texts **Cognitive Restrictions**Provides assistance to read and recognise important elements **Epileptics**Animations are deactivated and dangerous colour combinations reduced **ADHD settings**Distractions are reduced and a clear focus is set **Blind People**The screen reader can recognise contents of the web page **Motor impaired people**The website can be navigated via keyboard **Reset all settings**Your adjustments for accessibility are set back to the standard settings Black / white Hide images Highlighting Mouse Simple font Stop animations Mute sound Reading Mask Magnifier Highlight link Large pointer Virtual keyboard Saturation Contrast Video **Hide digi·smartPlugin?

** Once hidden, it will only be available again by deleting your browser data. Do you want to continue? You have accessedhttps://www.

emdgroup. com, but for users from your part of the world, we originally designed the following web presencehttps://www. merckgroup.

com. Internet Explorer is not supported You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser {"analytics":"targeting"} Publication of Merck KGaA, Darmstadt, Germany.

In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD. [](https://www. merckgroup.

com/en. html) Vibrant Science & Technology We are a vibrant team of specialists in Electronics, Healthcare and Life Science. We share a love of science and a passion for technology.

* Sustainability Statement Digital Ethics Company Info Our sustainability strategy Company Info Our ideas are everywhere – they can be life-changing, influencing how we tackle major illness, or be integral to the objects we rely on every day.

* Cardiovascular, Metabolism and Endocrinology * Metrology and Inspection * Delivery Systems & Services (DS&S) * The Future Transformation Blog Potential of mRNA Technology Stories AI – growth driver or glorified pocket calculator?

Stories Vibrant Thoughts Blog Stories Research is at the heart of everything we do At Merck KGaA, Darmstadt, Germany we translate science and technology into internal innovation and external partnerships that have the power to changes lives. Now more than ever, we’re keeping digitalization at the forefront of it all.

* Artificial Intelligence - AI Research Our Periodic Table of Elements App Applications & Industry Smart Manufacturing: Transforming the Factory Shopfloor Company Info Envisioning Tomorrow Stories Explore the latest news from the media center and stay up-to-date with our upcoming events.

What is mRNA Applications & Industry My Top 6: What the crisis has taught us Stories Compliance-Hotline Contacts The investors' section of Merck KGaA, Darmstadt, Germany provides everything shareholders and potential investors need to know about the company. Guidance for 2025 Delivered, Growth Foundation in Place Company Info Annual General Meeting 2026 Company Info Reports & Financials Company Info We love searching for answers.

Type to search. 0 matching results. Select 'Show All Results' link to see additional results Start your customer experience with us!

Build what's next with us. [](https://www. merckgroup.

com/en. html) 0 matching results. Select 'Show All Results' link to see additional results Start your customer experience with us!

Build what's next with us. 8. Sustainability Statement 2.

Neurology & Immunology 4. Cardiovascular, Metabolism and Endocrinology 4. Metrology and Inspection 5.

Delivery Systems & Services (DS&S) 8. The Future Transformation Blog 5. Artificial Intelligence - AI Research 2.

Events & Presentations EN You are currently browsing content in English 1. [](https://www. merckgroup.

com/en/research/open-innovation/research-grants. html)[](https://www. merckgroup.

com/en/research/open-innovation/email) 2. [](https://www. merckgroup.

com/en/research/open-innovation/research-grants. html)[](https://facebook. com/) 3.

[](https://www. merckgroup. com/en/research/open-innovation/research-grants.

html)[](https://linkedin. com/) 4. [](https://www.

merckgroup. com/en/research/open-innovation/research-grants. html)[](https://x.

com/) 5. [](https://www. merckgroup.

com/en/research/open-innovation/research-grants. html)[](https://wechat. com/) 6.

[](https://www. merckgroup. com/en/research/open-innovation/research-grants.

html)[](https://xing. com/) Share Icons revealed to the left Congo Democratic Republic #### Stimulating innovative research Since 2018, we have been offering research grants to encourage innovation in key areas that will shape the future. Grants of up to 500,000€ per year for up to 3 years have been made available.

In 2026, grants are available in the areas further specified below. * **In-vitro models and assays to identify novel therapies for neuroinflammatory diseases**- one grant of up to 250,000 EUR per year for up to 2 years. * **Artificial intelligence in cell culture media and process development**- one grant of up to 150,000 EUR per year for up to 3 years.

* **Innovative approaches to economical remediation of contaminated high volume materials**- one grant of up to 150,000 EUR per year for up to 2 years. * **Condensate-based high-sensitivity cell-free screening assays for the modulation of protein-protein interactions**- one grant of up to 100,000 EUR per year for up to 3 years.

* **Advancing molecule synthesis and discovery**- up to 3 grants each comprising a 1-year full Synthia® Retrosynthesis Software license, training, and extensive interaction with our scientists. Submission deadline for the 2026 Research Grants is 31 August 2026.

#### About the 2026 research grants The Research Grants program is open to scientists in all career stages who are affiliated with any research-based institution, university or company. In the first stage of the Research Grants application process, applicants submit their application containing non-confidential information only. You may apply for more than one grant.

If your application passes the first evaluation stage you are invited to submit a full proposal under confidentiality and join a deep-dive workshop. All applicants are informed about the decision of the selection committee. The second stage of the Research Grant process is a collaborative step, the deep-dive workshop.

Finalists submit their full proposal and then work together with our managers and scientists to jointly optimize their submitted project proposal. All teams reaching this stage will be informed in October. The deep-dive workshops are currently scheduled to take place in November and December 2026.

The culmination of the deep-dive workshops will be the selection of the research grant winners. #### Research Grant Funding The third stage of the Research Grants process is the Research Grant funding phase. To enable pay-out and project start, we enter into bilateral collaboration agreements with the winning recipients.

Our collaborative Research Grants are a unique opportunity for researchers who are interested in working with our scientists and receiving guidance from industry. During the Research Grant funding period, there will therefore be regular meetings with our scientists.

## In-vitro models & assays to identify novel therapies for neuroinflammatory diseases In this category, we are providing financial support for a proposal to develop predictive in-vitro models aimed at identifying and optimizing novel small molecule medicines for human neuroinflammatory diseases.

#### In-vitro models & assays to identify novel therapies for neuroinflammatory disease In this category, we invite proposals to develop predictive in-vitro models aimed at identifying and optimizing novel small molecule medicines for human neuroinflammatory diseases.

Parkinson’s disease (PD) is the fastest-growing neurodegenerative disorder affecting more than 10 million people worldwide and roughly 1% of those over 60 years of age [1]. All currently approved treatments are symptomatic, with no disease-modifying therapies available [2].

Repeated late-stage failures are largely attributed to the lack of translatability of existing animal models and to the heterogeneity of human pathology [3], highlighting an urgent need for physiologically relevant human-centered in-vitro models. We are specifically interested in preclinical in-vitro models that: * recapitulate the cellular microenvironment affected by neuroinflammation. * are amenable to medium-high throughput assays.

Examples of these are a co-culture system containing patient iPSC-derived neurons, astrocytes, oligodendrocytes and active microglia. * are amenable to pharmacological and genomic manipulations.

In your application, please include evidence that your proposed model would recapitulate: * Essential features of the neuro-immune axis, including active microglial-neuronal crosstalk, innate immunocompetence, and dynamic responses to several inflammatory stimuli. * Readouts could be quantification of cytokines, morphological changes and (neurotoxic) protein aggregations.

We are offering one grant of up to 250,000 EUR / year for up to 2 years. [1] https://pmc. ncbi.

nlm. nih. gov/articles/PMC10051786/ [2] https://link.

springer. com/article/10. 1007/s00702-023-02641-6 [3] https://www.

sciencedirect.

com/science/article/pii/S1353802016304631 ## Artificial intelligence in cell culture media and process development In this category, we invite proposals for robust, host-agnostic, and easy to parameterize models, in order to more quickly develop fit-for-purpose solutions for the optimization of bioprocesses for a broad base of host organisms #### Artificial intelligence in cell culture media and process development In this category, we invite proposals for robust, host-agnostic, and easy to parameterize models, that enable us to more quickly develop fit-for-purpose solutions for the optimization of bioprocesses for a broad base of host organisms.

In order to predict optimized media feeds for bioprocessing, we aim to use mechanistic and/or hybrid modeling to better understand the nutrient requirements of mammalian cell lines. However, although some advances have been recently demonstrated, it remains challenging to derive generic models for the optimization of upstream bioprocesses.

Recent developments and increase in computational power have opened the path for the application of artificial intelligence in the understanding of complex biological systems such as CHO cells or HEK293 cells used for the manufacturing of protein therapeutics, vaccines, and cell and gene therapies.

An increase in process efficiency would save resources, making biopharmaceutical drug manufacturing more sustainable and more affordable, assure highest standards of product quality, and allow access to wider patient populations.

Your proposal should include: * a non-confidential description of your model and key parameters relevant for optimizing cell culture media * the proposed data strategy for continuous improvement ensuring the model’s ability to adapt to a range of mammalian host organisms We are offering up to 1 grant of up up to 150,000 EUR per year for up to 3 years with the possibility of further collaboration.

## Innovative Approaches to Economical Remediation of Contaminated High Volume Materials In this category, we are calling for research proposals dedicated to the remediation of high-volume, low-contaminated soil and water, with a specific focus on chloro-organic pollutants and particularly those contaminated with hexachlorocyclohexane (HCH).

#### Innovative Approaches to Economical Remediation of Contaminated High Volume Materials The legacy of certain at the time legally-compliant, now abandoned processes has resulted in contaminated soils, wastewater, and groundwater, which continue to challenge communities and industries alike.

In particular, low-contaminated materials present significant difficulties for sustainable and economical remediation due to their typically high volumes. As a science-driven organisation, we are committed to fostering innovations that promote sustainability within our industry.

We are therefore calling for research proposals dedicated to the remediation of high-volume, low-contaminated soil and water, with a specific focus on chloro-organic pollutants and particularly those contaminated with hexachlorocyclohexane (HCH). We invite proposals that explore innovative, sustainable, scalable, and economically viable remediation methods.

Proposals should mandatorily outline practical feasibility in large-scale applications, contributing significantly to the advancement of environmental science and remediation technologies. We are offering 1 grant of up up to 150,000 EUR per year for up to 2 years with the possibility of further collaboration.

## Condensate-Based High-Sensitivity Cell-Free Screening Assays for the modulation of PPIs In this category, we are calling for research proposals to develop innovative cell free screening assays leveraging condensate-inspired approaches to study and modulate weak protein-protein interactions (PPIs).

#### Condensate-Based High-Sensitivity Cell-Free Screening Assays for the modulation of PPIs In this category, we invite proposals to develop innovative cell free screening assays leveraging condensate-inspired approaches to study and modulate weak protein protein interactions (PPIs).

Enhancing or disrupting PPIs by small molecules, such as molecular glue degraders or disruptors of functional complexes, is an emerging field in drug discovery. Current screening technologies, however, rely on standard methods that often lack sensitivity and fail to mimic cellular conditions.

In cells, local protein concentrations often are enhanced by sequestration into condensates—membrane-free compartments enriched with proteins, nucleic acids, and other macromolecules. This grant seeks innovative cell-free assays that replicate the crowded macromolecular environment of condensates in vitro, enabling better detection of weak PPIs and more accurate mimicry of cellular conditions.

In your application, please describe the anticipated sensitivity improvements and any additional advantages of your assay compared to traditional cell-free approaches. Additionally, specify the types of PPIs you aim to address. We are offering up to 1 grant of up up to 100,000 EUR per year for up to 3 years with the possibility of further collaboration.

## Advancing Molecule Synthesis and Discovery In this category, we are inviting research proposals for organic synthesis projects that you would like to advance using SYNTHIA® Retrosynthesis Software to enhance synthetic planning and accelerate lab completion.

#### Advancing Molecule Synthesis and Discovery We invite research proposals focused on the synthesis of novel molecules or the design and development of analogue compound libraries, including those intended for studying structure-activity relationships (SAR). SYNTHIA® Retrosynthesis Software is designed to empower chemists by simplifying and optimizing synthetic planning.

Leveraging over 20 years of development, this cutting-edge platform combines expert-coded organic synthesis rules with advanced algorithms to generate robust and viable pathways. With access to a database of over 12 million commercially available starting materials and building blocks, SYNTHIA® Retrosynthesis Software opens the door to a broad portfolio of innovative chemistry [1].

Submitted proposals should: * include a description of your synthetic project * be suitable for publication in a peer-reviewed journal * description of use of Synthia® in your project We are offering up to 3 research grants, each including a full SYNTHIA® Retrosynthesis Software license for one year and the opportunity for further collaboration.

Recipients will benefit from extensive interaction with our scientists, along with live training sessions on utilizing SYNTHIA® Retrosynthesis Software effectively. * How can I register on the submissions platform? How can I register on the submissions platform?

To submit an application, investigators must first register with our online portal. On your first visit, you need to register with a valid email address. * When is the application deadline?

When is the application deadline? Submissions will be accepted until 31 August 2026, 23. 59 Central European Summer Time.

How do I apply? In order to apply, fill out the application form with your research proposal, using non-confidential information only. Please make sure you have read and accepted the terms and conditions before you submit the application form.

* Are there any requirements for the attachments I can submit in addition to the abstract? Are there any requirements for the attachments I can submit in addition to the abstract? During the first phase of the application process, we only require title, abstract and information on the project team.

Additionally, you can add documents and graphics that explain the concept. There are no formal requirements for the attachments, most commonly used formats will work (for example, pdf or ppt). Please do not include any confidential information at this stage.

Get in touch with us in case you have issues uploading documents to the submissions portal on researchgrants@emdgroup. com. * Can I send in my application for more than one focus topic?

Can I send in my application for more than one focus topic? Yes, you should apply for those research topics that are relevant to your proposal and you may submit multiple applications. * My proposal fits well to the topic description but not sure that it addresses all aspects.

My proposal fits well to the topic description but not sure that it addresses all aspects. We only will disqualify proposals that fall entirely outside the scope of the grant description. Eligible proposals will be evaluated based on the criteria subject to the research grants terms and conditions.

These are currently **innovativeness, commercial potential, path forward after funding period ends, probability of success, team strength, strategic fit. ** What about publicity? Merck KGaA, Darmstadt, Germany retains the exclusive right to make any press release or any kind of public communication about the Grant and the Awardee(s).

Confidential details on project content are not revealed. * What is a Deep Dive workshop? What is a Deep Dive workshop?

During the deep-dive workshops, invited top submitters further advance their research proposals together with our scientists under confidentiality. For this purpose, a participant's agreement needs to be signed. At the end of the workshop, participants present their optimized research proposals and the winning applicants are selected.

* Where and when will the Deep Dive workshops take place? Where and when will the Deep Dive workshops take place? The deep-dive workshops are currently scheduled to take place in November 2026.

* When will the research grants be paid out? When will the research grants be paid out? Following the Deep Dive workshops, Merck KGaA, Darmstadt, Germany enters into bilateral collaboration agreements with the winning recipients to enable pay-out and project start.

During the collaboration, there will be regular meetings with our scientists. * What happens to applications that are not successful? What happens to applications that are not successful?

We will not reveal any information on submissions. In case your submission does not qualify to the next round, you will be notified by email. Please understand that due to the large number of applications we are not able to provide detailed feedback regarding the evaluation process at the abstract submission stage.

* Having technical problems with the submission platform? Having technical problems with the submission platform? Please drop us a mail on researchgrants@emdgroup.

com. ## Prior calls for research grants ### 350 Anniversary Grants First edition, our 2018 call for proposals. 1.

Healthy Lives / Drug Discovery 2. Life Reimagined / Synthetic Biology 4. Digitalization / Computing Our 2022 call for proposals.

2. Bioreactor design for culture meat 3. Next generation machine learning Our 2021 call for proposals.

2. Real time testing and sensors 3. Nanoparticle for nucleic acid delivery 7.

Media recycling for cultured meat Our 2022 call for proposals. 2. AI for diagnostics & target discovery 3.

Chemistry in the cloud 4. Sustainability in healthcare R&D 5. Innovation within green chemistry Our 2023 call for proposals Our 2024 Call for Research Grants 1.

Molecular Glue Degraders 2. Augmented Reality Digital Twin 3. AI-Driven Drug Discovery 1.

Smart Consumables for Biomanufacturing 2.

Multi-purpose Microphysiological Systems * Semiconductor Thin Films * Semiconductor Formulations * Metrology and Inspection * Delivery Systems and Services * Semiconductor Specialty Gases * Semiconductor Thin Films * Semiconductor Formulations * Metrology and Inspection * Delivery Systems and Services * Semiconductor Specialty Gases Publication of Merck KGaA, Darmstadt, Germany There are two different, unaffiliated companies that use the name MERCK.

Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name "Merck KGaA, Darmstadt, Germany," in the United States and Canada, and also uses"MilliporeSigma" in life science,"EMD Serono" in healthcare and "EMD Electronics" in the electronics business. The other company, Merck & Co. , Inc. holds the rights in the trademark MERCK in the United States and Canada.

Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world. To reflect such fact and to avoid any confusion, certain logos, terms and business description of the publication on this website have been substituted or modified, such as by referring to "Merck KGaA, Darmstadt, Germany" instead of "Merck" standing alone.

Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada. We are committed to an equitable hiring process for candidates from a diverse range of backgrounds. As part of this commitment, applicants with disabilities may be entitled to reasonable accommodations.

Please contact USLeavesandAccommodations@milliporesigma. com, if a reasonable accommodation is needed or if you otherwise need assistance to participate in the hiring process. { "hoverLabelAccessibe": "Accessibility"}